Pharmaceutical shares were pressured during the week as disappointing clinical
trial results weighed on big pharma's pipeline prospects. Biotech stocks exhibited
another week of strength but again came just short of a new high for the year.
The Amex Pharmaceutical Index (DRG) fell 1.1% last week while the Nasdaq Biotechnology
Index (NBI) rose to a weekly gain of 1.2%.